Cormedix Inc. (CRMD): Antony Pfaffle , Interim Chief Medical Officer of Cormedix Inc. sold 12,300 shares on May 18, 2016. The Insider selling transaction was reported by the company on May 20, 2016 to the Securities and Exchange Commission. The shares were sold at $3.01 per share for a total value of $34,682.58 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 17, 2016, Antony Pfaffle (Interim Chief Medical Officer) sold 60,000 shares at $2.74 per share price.On Jul 1, 2015, Randy Milby (CEO) purchased 1,610 shares at $3.88 per share price.Also, On Jun 25, 2015, Taunia Markvicka (director) purchased 4,000 shares at $4.81 per share price.On Jun 4, 2015, Matthew Duffy (director) sold 30,000 shares at $6.48 per share price.
Shares of CorMedix (CRMD) ended Thursday, May 19, 2016 session in red amid volatile trading. The shares closed down -0.26 points or -8.78% at $2.7 with 3,27,703 shares getting traded. Post opening the session at $2.92, the shares hit an intraday low of $2.6 and an intraday high of $2.97 and the price vacillated in this range throughout the day. The company has a market cap of $98 M and the number of outstanding shares has been calculated to be 3,62,18,323 shares. The 52-week high of CorMedix is $7.38 and the 52-week low is $1.15.
Company has been under the radar of several Street Analysts.CorMedix is Reiterated by FBR Capital to Outperform while Lowering the Price Target of the company shares to $ 6 from a previous price target of $7 . The Rating was issued on Mar 17, 2016.CorMedix is Initiated by FBR Capital to Outperform and the brokerage firm has set the Price Target at $7. The Rating was issued on Mar 3, 2016.
CorMedix Inc. (CorMedix) is a pharmaceutical company that in-licenses develops and commercializes prophylactic and therapeutic products for the treatment of infectious diseases in cardiac renal and oncology patients. The Company has in-licensed all of the products in its pipeline. The Company’s primary product is Neutrolin a catheter lock solution which is used the treatment of catheter-related infections and thrombosis in the central venous catheter markets such as dialysis critical care and oncology. It has the worldwide rights to develop and commercialize product candidates CRMD003 (Neutrolin) and CRMD004. The Company manufactures CRMD003 (Neutrolin) through Navinta LLC a United States-based active pharmaceutical ingredient (API) developer. The CRMD004 is the gel formulation of Neutrolin which is in the pre-clinical stage of development.